|
107
|
269
|
3sp9A |
Structural basis for iloprost as a dual pparalpha/delta agonist |
|
83
|
229
|
3ruuA |
Fxr with src1 and gsk237 |
|
82
|
228
|
3rvfA |
Fxr with src1 and gsk2034 |
|
87
|
229
|
3rutA |
Fxr with src1 and gsk359 |
|
97
|
246
|
3rllA |
Crystal structure of the t877a androgen receptor ligand binding domain in complex with (s)-n-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanonaphthalen-1-yloxy)-2-hydroxy-2-methylpropanamide |
|
99
|
247
|
3rljA |
Crystal structure of the androgen receptor ligand binding domain in complex with sarm s-22 |
|
101
|
329
|
5uanB |
Crystal structure of multi-domain rar-beta-rxr-alpha heterodimer on dna |
|
76
|
230
|
6a60D |
Crystal structure of human fxr/rxr-lbd heterodimer bound to gw4064 and 9cra and src1 |
|
93
|
270
|
3r8iA |
Crystal structure of ppargamma with an achiral ureidofibrate derivative (rt86) |
|
92
|
290
|
3r8dA |
Activation of the human nuclear xenobiotic receptor pxr by the reverse transcriptase-targeted anti-hiv drug pnu-142721 |
|
83
|
264
|
3r8aA |
X-ray crystal structure of the nuclear hormone receptor ppar-gamma in a complex with a compound with dual ppar gamma agonism and angiotensin ii type i receptor antagonism activity |
|
96
|
252
|
5xzhA |
Vitamin d receptor with a synthetic ligand adro2 |
|
97
|
249
|
2oz7A |
Crystal structure of the human androgen receptor t877a mutant ligand-binding domain with cyproterone acetate |
|
106
|
271
|
5y2oA |
Structure of ppargamma ligand binding domain-pioglitazone complex |
|
101
|
250
|
5xpnA |
Crystal structure of vdr-lbd complexed with 25rs-(hydroxyphenyl)-25-methoxy-2-methylidene-19,26,27-trinor-1-hydroxyvitamin d3 |
|
96
|
250
|
5xpoA |
Crystal structure of vdr-lbd complexed with 25-(hydroxyphenyl)-2-methylidene-19,26,27-trinor-25-oxo-1-hydroxyvitamin d3 |
|
95
|
250
|
5xppA |
Crystal structure of vdr-lbd complexed with 25rs-(hydroxyphenyl)-2-methylidene-19,26,27-trinor-1,25-dihydroxyvitamin d3 |
|
103
|
249
|
2q7jA |
The wild type androgen receptor ligand binding domain bound with testosterone and a tif2 box 3 coactivator peptide 740-753 |
|
95
|
250
|
5xplA |
Crystal structure of vdr-lbd complexed with 22s-butyl-25-hydroxyphenyl-2-methylidene-19,26,27-trinor-25-oxo-1-hydroxyvitamin d3 |
|
85
|
235
|
5x8sA |
Crystal structure of the mutant human ror gamma ligand binding domain with ursolic acid. |
|
90
|
291
|
5x0rA |
Crystal structure of pxr lbd complexed with sjb7 |
|
98
|
244
|
5x8uA |
Crystal structure of the wild human ror gamma ligand binding domain. |
|
74
|
228
|
5wzxA |
Structural basis for a pentacyclic oleanane-type triterpenoid as a ligand of fxr |
|
92
|
269
|
5wr0A |
Huisgen cycloaddition for pparg-lbd labeling by soaking method |
|
96
|
269
|
5wqxA |
Covalent bond formation of synthetic ligand with hpparg-lbd |
|
92
|
244
|
5w9dA |
Estrogen receptor alpha ligand binding domain c381s, c417s, c530s mutant in complex with endoxifen |
|
85
|
239
|
5w9cA |
Estrogen receptor alpha ligand binding domain c381s, c417s, c530s in complex with 4-hydroxytamoxifen |
|
94
|
259
|
5vqkA |
X-ray co-structure of nuclear receptor ror-gammat ligand binding domain with a inverse agonist and src2 peptide |
|
96
|
250
|
5vo4A |
Crystal structure of the androgen receptor ligand binding domain in complex with 5-(2-fluoro-4-hydroxyphenyl)-1-methyl-1h-pyrrole-2-carbonitrile |
|
99
|
259
|
5vqlA |
X-ray co-structure of nuclear receptor ror-gammat ligand binding domain with a inverse agonist and src2 peptide |
|
94
|
259
|
5vb5A |
X-ray co-structure of nuclear receptor ror-gammat ligand binding domain with an inverse agonist and src2 peptide |
|
98
|
259
|
5vb7A |
X-ray co-structure of nuclear receptor ror-gammat ligand binding domain with an agonist and src2 peptide |
|
96
|
249
|
5v8qA |
Synthesis and biological evaluation of novel selective androgen receptor modulators (sarms): part iii |
|
99
|
259
|
5vb6A |
X-ray co-structure of nuclear receptor ror-gammat ligand binding domain with an inverse agonist and src2 peptide |
|
94
|
239
|
5unjA |
Structure of human liver receptor homolog 1 in complex with pgc1a and rjw100 |
|
87
|
223
|
5ufrA |
Structure of rorgt bound to |
|
96
|
272
|
5u5lA |
X-ray crystal structure of the ppargamma ligand binding domain in complex with rivoglitazone |
|
89
|
240
|
5ufwA |
Estrogen receptor alpha ligand binding domain in complex with op1154 |
|
110
|
271
|
5ugmA |
Crystal structure of human ppargamma ligand binding domain in complex with edaglitazone |
|
89
|
239
|
5ufxA |
Estrogen receptor alpha ligand binding domain in complex with op1074 |
|
105
|
269
|
5u3vA |
Human ppardelta ligand-binding domain in complexed with specific agonist 6 |
|
72
|
223
|
5uhiA |
Structure of rorgt bound to |
|
107
|
271
|
5u3sA |
Human ppardelta ligand-binding domain in complexed with specific agonist 3 |
|
93
|
251
|
5uc3A |
Nuclear receptor |
|
90
|
225
|
5ufoA |
Structure of rorgt bound to |
|
109
|
269
|
5u3qA |
Human ppardelta ligand-binding domain in complexed with specific agonist 1 |
|
100
|
268
|
5u45A |
Human ppardelta ligand-binding domain in complexed with specific agonist 14 |
|
105
|
267
|
5u3xA |
Human ppardelta ligand-binding domain in complexed with specific agonist 8 |
|
98
|
265
|
5u44A |
Human ppardelta ligand-binding domain in complexed with specific agonist 13 |
|
102
|
265
|
5u40A |
Human ppardelta ligand-binding domain in complexed with specific agonist 15 |
